Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation.
Hematol Oncol Clin North Am
; 14(2): 445-57, x, 2000 Apr.
Article
en En
| MEDLINE
| ID: mdl-10806566
The authors attempted experimental and clinical use of argatroban as an alternative anticoagulant in left heart bypass with the centrifugal pump, percutaneous cardiopulmonary support (PCPS), and extracorporeal membrane oxygenation (ECMO) to determine if it has complementary effects in preventing thrombus formation without aggravating bleeding tendency. Its reversible binding to thrombin and its short half-life contributed to reduce the risk of excessive blood loss without clot formation within the extracorporeal circulation circuit during thoracic aortic surgery using left heart bypass. PCPS and ECMO were safely performed at doses ranging from 0.5 to 10 micrograms/kg/min to maintain activated clotting time at approximately 200 seconds. Although experimental studies showed argatroban to be advantageous in preserving platelet and fibrinogen, further clinical investigations are necessary.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ácidos Pipecólicos
/
Circulación Extracorporea
/
Anticoagulantes
Límite:
Animals
/
Child
/
Humans
Idioma:
En
Revista:
Hematol Oncol Clin North Am
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
Año:
2000
Tipo del documento:
Article
País de afiliación:
Japón
Pais de publicación:
Estados Unidos